Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 29, 2017 09:15 ET | Source: Advanced Accelerator Applications

Advanced Accelerator Applications Announces European Approval of Lutetium (177Lu) Oxodotreotide (Lutathera®) for Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors

SAINT-GENIS-POUILLY, France, Sept. 29, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), an international specialist in Molecular Nuclear Medicine...
September 06, 2017 11:02 ET | Source: Advanced Accelerator Applications

CORRECTING and REPLACING -- Advanced Accelerator Applications S.A.

SAINT-GENIS-POUILLY, France, Sept. 06, 2017 (GLOBE NEWSWIRE) -- In a release issued earlier today by Advanced Accelerator Applications S.A. (NASDAQ:AAAP), please note that the headline has been...
September 06, 2017 07:00 ET | Source: Advanced Accelerator Applications

Advanced Accelerator Applications and FUJIFILM RI Pharma, Co., LTD Announce First Patient in Bridging Study in Japan for Lutetium Lu 177 Dotatate* (Lutathera®)

SAINT-GENIS-POUILLY, France, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), an international specialist in Molecular Nuclear Medicine...
August 31, 2017 07:00 ET | Source: Advanced Accelerator Applications

Advanced Accelerator Applications Reports 32% Sales Growth for Second Quarter 2017

Positive CHMP Opinion for Lutetium Lu 177 Dotatate* (Lutathera®) for GEP-NETS FDA Acknowledged Receipt and Completeness of NDA Resubmission for Lutetium Lu 177 Dotatate* (Lutathera®) and Provided...
August 28, 2017 10:07 ET | Source: Advanced Accelerator Applications

Advanced Accelerator Applications Announces New Prescription Drug User Fee Act (PDUFA) date of January 26, 2018, for Lutetium Lu 177 Dotatate (Lutathera®)

SAINT-GENIS-POUILLY, France, Aug. 28, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), an international specialist in Molecular Nuclear Medicine...
July 27, 2017 07:00 ET | Source: Advanced Accelerator Applications

Advanced Accelerator Applications Completes Resubmission of NDA for Lutetium Lu 177 Dotatate (Lutathera®) to FDA

SAINT-GENIS-POUILLY, France, July 27, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), an international specialist in Molecular Nuclear Medicine...
July 21, 2017 08:29 ET | Source: Advanced Accelerator Applications

Advanced Accelerator Applications Announces Positive CHMP Opinion Recommending Approval of Lutetium 177Lu Oxodotreotide (Lutathera®) for Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors

SAINT-GENIS-POUILLY, France, July 21, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), an international specialist in Molecular Nuclear Medicine...
May 31, 2017 07:00 ET | Source: Advanced Accelerator Applications

Advanced Accelerator Applications Reports 21% Sales Growth for First Quarter 2017

On Track to Resubmit NDA for lutetium Lu 177 dotatate (Lutathera®) to FDA in Mid-2017 NETSPOT® Unit Sales per Month Jump 140% During First Quarter First Quarter 2017 Highlights: Advanced...
May 30, 2017 08:36 ET | Source: Advanced Accelerator Applications; Blue Earth Diagnostics Ltd.

Advanced Accelerator Applications and Blue Earth Diagnostics Announce European Manufacturing and Distribution Agreements for Axumin™ (Fluciclovine (18F)) for PET Imaging of Recurrent Prostate Cancer

SAINT-GENIS-POUILLY, France and OXFORD, UK, May 30, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA), an international specialist in Molecular Nuclear Medicine,...
May 25, 2017 07:00 ET | Source: Advanced Accelerator Applications

Advanced Accelerator Applications Appoints Christine Mikail to Board of Directors

SAINT-GENIS-POUILLY, France, May 25, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), an international specialist in Molecular Nuclear Medicine...